Predicted Structures for Kappa Opioid G-Protein Coupled Receptor Bound to Selective Agonists

Human kappa opioid receptor (κ-OR), a G protein-coupled receptor (GPCR), has been identified as a drug target for treatment of such human disorders as pain perception, neuroendocrine physiology, affective behavior, and cognition. In order to find more selective and active agonists, one would like to do structure based drug design. Indeed, there is an X-ray structure for an antagonist bound to κ-OR, but structures for activated GPCRs are quite different from those for the inactive GPCRs. Here we predict the ensemble of 24 low-energy structures of human kappa opioid receptor (κ-OR), obtained by application of the GEnSeMBLE (GPCR Ensemble of Structures in Membrane Bilayer Environment) complete sampling method, which evaluates 13 trillion combinations of tilt and rotation angles for κ-OR to select the best 24. To validate these structures, we used the DarwinDock complete sampling method to predict the binding sites for five known agonists (ethylketocyclazocine, bremazocine, pentazocine, nalorphine, and morphine) bound to all 24 κ-OR conformations. We find that some agonists bind selectively to receptor conformations that lack the salt bridge between transmembrane domains 3 and 6 as expected for active conformations. These 3D structures for κ-OR provide a structural basis for understanding ligand binding and activation of κ-OR, which should be useful for guiding subtype specific drug design.

[1]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[2]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[3]  T. Creamer,et al.  Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides. , 1996, Biochemistry.

[4]  Xufeng Sun,et al.  Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. , 2003, Journal of medicinal chemistry.

[5]  Juanita Dortch-Carnes,et al.  Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. , 2005, CNS drug reviews.

[6]  Michael Berlin,et al.  Histamine H3 receptor as a drug discovery target. , 2011, Journal of medicinal chemistry.

[7]  G. Pasternak,et al.  An opiate-receptor gene family reunion , 1994, Trends in Neurosciences.

[8]  W. Goddard,et al.  Structure prediction of G protein-coupled receptors and their ensemble of functionally important conformations. , 2012, Methods in molecular biology.

[9]  B. Bloch,et al.  kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. N. Brogden,et al.  Pentazocine: A Review of its Pharmacological Properties, Therapeutic Efficacy and Dependence Liability , 2012, Drugs.

[11]  W. Goddard,et al.  Conformational ensemble view of G protein-coupled receptors and the effect of mutations and ligand binding. , 2013, Methods in enzymology.

[12]  N. Yamaotsu,et al.  3D-Pharmacophore Identification for κ-Opioid Agonists Using Ligand-Based Drug-Design Techniques , 2010 .

[13]  H. Emrich,et al.  Psychotomimesis mediated by kappa opiate receptors , 1986, Science.

[14]  W. Goddard,et al.  Use of G-Protein-Coupled and -Uncoupled CCR5 Receptors by CCR5 Inhibitor-Resistant and -Sensitive Human Immunodeficiency Virus Type 1 Variants , 2013, Journal of Virology.

[15]  Yoshinori Shichida,et al.  Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[17]  Tsutomu Kouyama,et al.  Crystal structure of squid rhodopsin , 2008, Nature.

[18]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[19]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[20]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[21]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[22]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[23]  Brian K. Kobilka,et al.  High resolution crystal structure of human B2-adrenergic G protein-coupled receptor. , 2007 .

[24]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[25]  Xavier Deupi,et al.  Structural insights into agonist-induced activation of G-protein-coupled receptors. , 2011, Current opinion in structural biology.

[26]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[27]  Jun Tan,et al.  3D Structure Prediction of TAS2R38 Bitter Receptors Bound to Agonists Phenylthiocarbamide (PTC) and 6-n-Propylthiouracil (PROP) , 2012, J. Chem. Inf. Model..

[28]  William A. Goddard,et al.  SuperBiHelix method for predicting the pleiotropic ensemble of G-protein–coupled receptor conformations , 2013, Proceedings of the National Academy of Sciences.

[29]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[30]  Caitlin E. Scott,et al.  Molecular basis for dramatic changes in cannabinoid CB1 G protein‐coupled receptor activation upon single and double point mutations , 2013, Protein science : a publication of the Protein Society.

[31]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[32]  Jiyoung Heo,et al.  Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor , 2012, Proceedings of the National Academy of Sciences.

[33]  William A. Goddard,et al.  How broadly tuned olfactory receptors equally recognize their agonists. Human OR1G1 as a test case , 2012, Cellular and Molecular Life Sciences.

[34]  J. M. Kennedy,et al.  Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. , 1998, NIDA research monograph.

[35]  W. Goddard,et al.  Characterizing and predicting the functional and conformational diversity of seven-transmembrane proteins. , 2011, Methods.

[36]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[37]  K. Garcia,et al.  Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors. , 2008, Biochemistry.

[38]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[39]  P. Glare,et al.  Clinical pharmacokinetics of morphine. , 1991, Therapeutic drug monitoring.

[40]  Juanita Dortch-Carnes,et al.  Bremazocine: A κ-Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties , 2006 .

[41]  M. Waldhoer,et al.  Opioid receptors. , 2004, Annual review of biochemistry.

[42]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[43]  C. Chavkin,et al.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.

[44]  Nagarajan Vaidehi,et al.  Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. , 2008, Biophysical journal.

[45]  Ravinder Abrol,et al.  Bihelix: Towards de novo structure prediction of an ensemble of G‐protein coupled receptor conformations , 2012, Proteins.

[46]  G. Pasternak,et al.  Pharmacological characterization of nalorphine, a kappa 3 analgesic. , 1991, The Journal of pharmacology and experimental therapeutics.

[47]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[48]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[49]  Gebhard F. X. Schertler,et al.  The structural basis of agonist-induced activation in constitutively active rhodopsin , 2011, Nature.

[50]  Tetsuya Hori,et al.  Crystal Structure of Squid Rhodopsin with Intracellularly Extended Cytoplasmic Region , 2008, Journal of Biological Chemistry.

[51]  Stephen Taylor,et al.  Molecular dynamics for very large systems on massively parallel computers: The MPSim program , 1997, J. Comput. Chem..

[52]  S. Joel,et al.  Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine‐6‐glucuronide , 1990, Clinical pharmacology and therapeutics.

[53]  Bartosz Trzaskowski,et al.  Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor , 2014, Proceedings of the National Academy of Sciences.

[54]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[55]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[56]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[57]  P B Bradley,et al.  International Union of Pharmacology. XII. Classification of opioid receptors. , 1996, Pharmacological reviews.

[58]  Structure. Rhodopsin sees the light. , 2000, Science.

[59]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[60]  E. Meng,et al.  Rhodopsin Sees the Light , 2000, Science.

[61]  Sharon Brunett,et al.  Molecular dynamics for very large systems on massively parallel computers: The MPSim program , 1997 .

[62]  K. Williams,et al.  Importance of Drug Enantiomers in Clinical Pharmacology , 1985, Drugs.

[63]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[64]  Vadim Cherezov,et al.  Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.

[65]  W. Goddard,et al.  Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor , 2011, Proteins.

[66]  E Novellino,et al.  Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. , 2000, Journal of medicinal chemistry.

[67]  H. Kosterlitz,et al.  Bremazocine is an agonist at K‐opioid receptors and an antagonist at μ‐opioid receptors in the guinea‐pig myenteric plexus , 1986, British journal of pharmacology.

[68]  Nagarajan Vaidehi,et al.  The role of conformational ensembles in ligand recognition in G-protein coupled receptors. , 2011, Journal of the American Chemical Society.

[69]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[70]  T. Kenakin,et al.  The role of conformational ensembles of seven transmembrane receptors in functional selectivity. , 2010, Current opinion in pharmacology.

[71]  A. Keats,et al.  Nalorphine, a potent analgesic in man. , 1956, The Journal of pharmacology and experimental therapeutics.

[72]  Cheng Zhang,et al.  Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.

[73]  L. Pasquinucci,et al.  Non-peptide ligands for opioid receptors. Design of kappa-specific agonists. , 1993, Journal of medicinal chemistry.

[74]  Xavier Deupi,et al.  The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex , 2009, Proceedings of the National Academy of Sciences.

[75]  W. Goddard,et al.  Flat-Bottom Strategy for Improved Accuracy in Protein Side-Chain Placements. , 2008, Journal of chemical theory and computation.

[76]  G. Pasternak Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Caitlin E. Scott,et al.  Computationally‐predicted CB1 cannabinoid receptor mutants show distinct patterns of salt‐bridges that correlate with their level of constitutive activity reflected in G protein coupling levels, thermal stability, and ligand binding , 2013, Proteins.

[78]  G. Uhl,et al.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. , 1994, The Journal of biological chemistry.

[79]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[80]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[81]  Jerzy Ciarkowski,et al.  Molecular dynamics study of the internal water molecules in vasopressin and oxytocin receptors. , 2009, Protein and peptide letters.

[82]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[83]  Oliver P. Ernst,et al.  Crystal structure of metarhodopsin II , 2011, Nature.

[84]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[85]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[86]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[87]  S. L. Mayo,et al.  DREIDING: A generic force field for molecular simulations , 1990 .

[88]  Cécile Béguin,et al.  Kappa-opioid ligands in the study and treatment of mood disorders. , 2009, Pharmacology & therapeutics.